Bluejay touts positive data for chronic hepatitis D treatment
The biopharma shared preliminary Phase II data at EASL for its IgG1 monoclonal antibody, BJT-778
The biopharma shared preliminary Phase II data at EASL for its IgG1 monoclonal antibody, BJT-778
What's Your Reaction?
